662 related articles for article (PubMed ID: 30833752)
1. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
Bryant KL; Stalnecker CA; Zeitouni D; Klomp JE; Peng S; Tikunov AP; Gunda V; Pierobon M; Waters AM; George SD; Tomar G; Papke B; Hobbs GA; Yan L; Hayes TK; Diehl JN; Goode GD; Chaika NV; Wang Y; Zhang GF; Witkiewicz AK; Knudsen ES; Petricoin EF; Singh PK; Macdonald JM; Tran NL; Lyssiotis CA; Ying H; Kimmelman AC; Cox AD; Der CJ
Nat Med; 2019 Apr; 25(4):628-640. PubMed ID: 30833752
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
Stalnecker CA; Grover KR; Edwards AC; Coleman MF; Yang R; DeLiberty JM; Papke B; Goodwin CM; Pierobon M; Petricoin EF; Gautam P; Wennerberg K; Cox AD; Der CJ; Hursting SD; Bryant KL
Cancer Res; 2022 Feb; 82(4):586-598. PubMed ID: 34921013
[TBL] [Abstract][Full Text] [Related]
3. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
[TBL] [Abstract][Full Text] [Related]
4. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Kinsey CG; Camolotto SA; Boespflug AM; Guillen KP; Foth M; Truong A; Schuman SS; Shea JE; Seipp MT; Yap JT; Burrell LD; Lum DH; Whisenant JR; Gilcrease GW; Cavalieri CC; Rehbein KM; Cutler SL; Affolter KE; Welm AL; Welm BE; Scaife CL; Snyder EL; McMahon M
Nat Med; 2019 Apr; 25(4):620-627. PubMed ID: 30833748
[TBL] [Abstract][Full Text] [Related]
5. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas.
Bildik G; Gray JP; Mao W; Yang H; Ozyurt R; Orellana VR; De Wever O; Carey MS; Bast RC; Lu Z
Autophagy; 2024 Mar; 20(3):675-691. PubMed ID: 38169324
[TBL] [Abstract][Full Text] [Related]
6. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
Diehl JN; Klomp JE; Snare KR; Hibshman PS; Blake DR; Kaiser ZD; Gilbert TSK; Baldelli E; Pierobon M; Papke B; Yang R; Hodge RG; Rashid NU; Petricoin EF; Herring LE; Graves LM; Cox AD; Der CJ
J Biol Chem; 2021 Nov; 297(5):101335. PubMed ID: 34688654
[TBL] [Abstract][Full Text] [Related]
7. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
Waters AM; Khatib TO; Papke B; Goodwin CM; Hobbs GA; Diehl JN; Yang R; Edwards AC; Walsh KH; Sulahian R; McFarland JM; Kapner KS; Gilbert TSK; Stalnecker CA; Javaid S; Barkovskaya A; Grover KR; Hibshman PS; Blake DR; Schaefer A; Nowak KM; Klomp JE; Hayes TK; Kassner M; Tang N; Tanaseichuk O; Chen K; Zhou Y; Kalkat M; Herring LE; Graves LM; Penn LZ; Yin HH; Aguirre AJ; Hahn WC; Cox AD; Der CJ
Cell Rep; 2021 Jun; 35(13):109291. PubMed ID: 34192548
[TBL] [Abstract][Full Text] [Related]
8. The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation.
Loncle C; Molejon MI; Lac S; Tellechea JI; Lomberk G; Gramatica L; Fernandez Zapico MF; Dusetti N; Urrutia R; Iovanna JL
Cell Death Dis; 2016 Jul; 7(7):e2295. PubMed ID: 27415425
[TBL] [Abstract][Full Text] [Related]
9. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
Diehl JN; Hibshman PS; Ozkan-Dagliyan I; Goodwin CM; Howard SV; Cox AD; Der CJ
Adv Cancer Res; 2022; 153():101-130. PubMed ID: 35101228
[TBL] [Abstract][Full Text] [Related]
10. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
[TBL] [Abstract][Full Text] [Related]
11. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
[TBL] [Abstract][Full Text] [Related]
12. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
13. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ
Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168
[TBL] [Abstract][Full Text] [Related]
14. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to autophagy inhibition is enhanced by dual IGF1R and MAPK/ERK inhibition in pancreatic cancer.
Stalnecker CA; Coleman MF; Bryant KL
Autophagy; 2022 Jul; 18(7):1737-1739. PubMed ID: 35201948
[TBL] [Abstract][Full Text] [Related]
17. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
Klomp JA; Klomp JE; Stalnecker CA; Bryant KL; Edwards AC; Drizyte-Miller K; Hibshman PS; Diehl JN; Lee YS; Morales AJ; Taylor KE; Peng S; Tran NL; Herring LE; Prevatte AW; Barker NK; Hover LD; Hallin J; Chowdhury S; Coker O; Lee HM; Goodwin CM; Gautam P; Olson P; Christensen JG; Shen JP; Kopetz S; Graves LM; Lim KH; Wang-Gillam A; Wennerberg K; Cox AD; Der CJ
Science; 2024 Jun; 384(6700):eadk0775. PubMed ID: 38843331
[TBL] [Abstract][Full Text] [Related]
18. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
19. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis.
Yan Z; Ohuchida K; Fei S; Zheng B; Guan W; Feng H; Kibe S; Ando Y; Koikawa K; Abe T; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Mizumoto K; Hashizume M; Nakamura M
J Exp Clin Cancer Res; 2019 May; 38(1):221. PubMed ID: 31133044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
